JP2013518912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518912A5 JP2013518912A5 JP2012552152A JP2012552152A JP2013518912A5 JP 2013518912 A5 JP2013518912 A5 JP 2013518912A5 JP 2012552152 A JP2012552152 A JP 2012552152A JP 2012552152 A JP2012552152 A JP 2012552152A JP 2013518912 A5 JP2013518912 A5 JP 2013518912A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- drug conjugate
- fragment
- antibody drug
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000611 antibody drug conjugate Substances 0.000 claims 33
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 33
- 239000012634 fragment Substances 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 11
- 108010059074 monomethylauristatin F Proteins 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 5
- 230000001268 conjugating effect Effects 0.000 claims 5
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 201000007270 liver cancer Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000004614 tumor growth Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000000562 conjugate Substances 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30248910P | 2010-02-08 | 2010-02-08 | |
| US61/302,489 | 2010-02-08 | ||
| PCT/US2011/024055 WO2011097627A1 (en) | 2010-02-08 | 2011-02-08 | Antibody drug conjugates (adc) that bind to 161p2f10b proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016223674A Division JP6529478B2 (ja) | 2010-02-08 | 2016-11-17 | １６１ｐ２ｆ１０ｂタンパク質に結合する抗体薬物コンジュゲート（ａｄｃ） |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518912A JP2013518912A (ja) | 2013-05-23 |
| JP2013518912A5 true JP2013518912A5 (OSRAM) | 2014-11-13 |
| JP6046494B2 JP6046494B2 (ja) | 2016-12-14 |
Family
ID=44355840
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552152A Active JP6046494B2 (ja) | 2010-02-08 | 2011-02-08 | １６１ｐ２ｆ１０ｂタンパク質に結合する抗体薬物コンジュゲート（ａｄｃ） |
| JP2016223674A Active JP6529478B2 (ja) | 2010-02-08 | 2016-11-17 | １６１ｐ２ｆ１０ｂタンパク質に結合する抗体薬物コンジュゲート（ａｄｃ） |
| JP2019091063A Pending JP2019131616A (ja) | 2010-02-08 | 2019-05-14 | １６１ｐ２ｆ１０ｂタンパク質に結合する抗体薬物コンジュゲート（ａｄｃ） |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016223674A Active JP6529478B2 (ja) | 2010-02-08 | 2016-11-17 | １６１ｐ２ｆ１０ｂタンパク質に結合する抗体薬物コンジュゲート（ａｄｃ） |
| JP2019091063A Pending JP2019131616A (ja) | 2010-02-08 | 2019-05-14 | １６１ｐ２ｆ１０ｂタンパク質に結合する抗体薬物コンジュゲート（ａｄｃ） |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8609092B2 (OSRAM) |
| EP (2) | EP3395361A1 (OSRAM) |
| JP (3) | JP6046494B2 (OSRAM) |
| KR (1) | KR101510413B1 (OSRAM) |
| CN (2) | CN106975082A (OSRAM) |
| AU (3) | AU2011213609B2 (OSRAM) |
| BR (1) | BR112012019780A2 (OSRAM) |
| CA (1) | CA2789230C (OSRAM) |
| EA (1) | EA201201120A1 (OSRAM) |
| ES (1) | ES2668645T3 (OSRAM) |
| IL (1) | IL221205A (OSRAM) |
| MX (1) | MX2012008884A (OSRAM) |
| PH (1) | PH12012501545B1 (OSRAM) |
| TW (1) | TWI504410B (OSRAM) |
| UA (1) | UA115517C2 (OSRAM) |
| WO (1) | WO2011097627A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA115517C2 (uk) * | 2010-02-08 | 2017-11-27 | Ейдженсіс, Інк. | Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b |
| US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
| AU2013229786B2 (en) | 2012-03-08 | 2017-06-22 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| EP2849797B1 (en) | 2012-05-15 | 2019-12-18 | Concortis Biosystems, Corp | Drug-conjugates, conjugation methods, and uses thereof |
| PT2887959T (pt) * | 2012-08-23 | 2019-02-01 | Seattle Genetics Inc | Conjugados anticorpo-fármaco (adc) que se ligam a proteínas 158p1d7 |
| US20150071923A1 (en) | 2013-09-12 | 2015-03-12 | Ge Wei | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
| BR112016007622A2 (pt) | 2013-10-15 | 2018-01-23 | Seattle Genetics, Inc. | composto, composição farmacêutica, conjugado de ligante-droga, e, método para tratar câncer |
| WO2015057876A1 (en) | 2013-10-15 | 2015-04-23 | Sorrento Therapeutics Inc. | Drug-conjugates with a targeting molecule and two different drugs |
| RU2016122041A (ru) * | 2013-11-06 | 2017-12-11 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Новые анти-клаудин антитела и способы их применения |
| US9239324B2 (en) * | 2013-12-06 | 2016-01-19 | Gang Chen | Antibody-binding protein-drug conjugate and methods of use |
| EP3250238B1 (en) | 2015-01-28 | 2022-06-01 | Sorrento Therapeutics, Inc. | Antibody drug conjugates |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| SG11201804268RA (en) | 2015-12-04 | 2018-06-28 | Seattle Genetics Inc | Conjugates of quaternized tubulysin compounds |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| BR112018069273A2 (pt) | 2016-03-25 | 2019-01-22 | Seattle Genetics Inc | métodos para preparação de um composto e para tratamento de um indivíduo com uma malignidade hematológica, composto, composição, e, intermediário ligante de fármaco ou composto ligante de fármaco |
| WO2018119314A1 (en) * | 2016-12-22 | 2018-06-28 | Ardeagen Corporation | Anti-ror1 antibody and conjugates thereof |
| US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
| EP3617221A4 (en) | 2017-04-19 | 2021-04-14 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | CYTOTOXIN AND CONJUGATE, USES THEREOF AND MANUFACTURING PROCESSES THEREFORE |
| CN119241554A (zh) | 2017-12-15 | 2025-01-03 | 四川科伦博泰生物医药股份有限公司 | 生物活性物偶联物及其制备方法和用途 |
| WO2019118937A1 (en) | 2017-12-15 | 2019-06-20 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| FI13575Y1 (fi) | 2018-09-24 | 2024-03-26 | Janssen Biotech Inc | IL12/IL23-vasta-aine käytettäväksi turvallisessa ja tehokaassa menetelmässä haavaisen paksusuolitulehduksen hoitamiseksi |
| AU2020208828A1 (en) | 2019-01-15 | 2021-08-05 | Janssen Biotech, Inc. | Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis |
| US20220073603A1 (en) | 2020-07-30 | 2022-03-10 | Janssen Biotech, Inc. | Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody |
| US20240269304A1 (en) | 2020-11-24 | 2024-08-15 | Novartis Ag | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| AU2022388735A1 (en) | 2021-11-09 | 2024-05-30 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
| WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| KR20250011947A (ko) | 2022-05-20 | 2025-01-22 | 노파르티스 아게 | 항체 약물 콘쥬게이트 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| US5001225A (en) * | 1986-12-08 | 1991-03-19 | Georgetown University | Monoclonal antibodies to a pan-malarial antigen |
| US5079233A (en) | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
| US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
| US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
| US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
| US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
| US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
| US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
| US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| DK0871490T3 (da) | 1995-12-22 | 2003-07-07 | Bristol Myers Squibb Co | Forgrenede hydrazonlinkere |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| DE69738077T2 (de) | 1996-10-15 | 2008-05-21 | The Regents Of The University Of California, Oakland | Tiermodelle für die menschliche prostatakrebsfortschreitung |
| DE69832158T2 (de) | 1997-02-25 | 2006-08-10 | Arizona Board Of Regents, Tempe | Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18 |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6323321B1 (en) * | 1997-03-05 | 2001-11-27 | Eberhard-Karls-Universitat Tubingen Universitatsklinikum | Antibody 97A6 |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1082463B1 (en) | 1998-05-15 | 2007-01-03 | Quark Biotech, Inc. | Mechanical stress induced genes, expression products therefrom, and uses thereof |
| WO2000021990A1 (en) | 1998-10-15 | 2000-04-20 | Genetics Institute, Inc. | SECRETED EXPRESSED SEQUENCE TAGS (sESTs) |
| US20020137139A1 (en) * | 1999-01-12 | 2002-09-26 | Byatt John C | Nucleic acid and other molecules associated with lactation and muscle and fat deposition |
| CN1308347C (zh) * | 1999-04-28 | 2007-04-04 | 德克萨斯大学董事会 | 用于通过选择性抑制vegf来治疗癌症的组合物和方法 |
| ATE280389T1 (de) * | 1999-05-19 | 2004-11-15 | Univ Eberhard Karls | Verwendung eines antikörpers zur detektion von basophilen und/oder mastzellen |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| GB2373500B (en) | 2000-02-04 | 2004-12-15 | Aeomica Inc | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
| WO2001060860A2 (en) | 2000-02-17 | 2001-08-23 | Millennium Predictive Medicine, Inc. | Genes differentially expressed in human prostate cancer and their use |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| US20060088823A1 (en) * | 2001-03-29 | 2006-04-27 | Brian Haab | Microarray gene expression profiling in clear cell renal cell carcinoma : prognosis and drug target identification |
| US7736654B2 (en) * | 2001-04-10 | 2010-06-15 | Agensys, Inc. | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
| US20030191073A1 (en) | 2001-11-07 | 2003-10-09 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
| US20050055733A1 (en) * | 2001-07-06 | 2005-03-10 | Zairen Sun | Small intestine and colon genes |
| AU2002324700A1 (en) | 2001-08-14 | 2003-03-03 | Bayer Ag | Nucleic acid and amino acid sequences involved in pain |
| AU2002361610B2 (en) * | 2001-11-07 | 2007-01-11 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
| DE10160921B4 (de) | 2001-12-06 | 2005-09-22 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Verfahren zum Nachweis von Allergien und Verwendung eines Antikörpers zum Nachweis von Allergien |
| CA2802205C (en) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| WO2004073656A2 (en) * | 2003-02-20 | 2004-09-02 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| NZ583292A (en) | 2003-11-06 | 2012-03-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| BRPI0509274A (pt) | 2004-03-26 | 2007-09-04 | Pfizer Prod Inc | usos de anticorpos anti-ctla-4 |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| RU2413735C2 (ru) * | 2005-03-31 | 2011-03-10 | Эдженсис, Инк. | Антитела и родственные молекулы, связывающиеся с белками 161p2f10b |
| US8350009B2 (en) * | 2005-03-31 | 2013-01-08 | Agensys, Inc. | Antibodies and related molecules that bind to 161P2F10B proteins |
| CN101500590A (zh) * | 2005-03-31 | 2009-08-05 | 阿根西斯公司 | 与161p2f10b蛋白结合的抗体和相关分子 |
| US20070160617A1 (en) | 2005-06-20 | 2007-07-12 | Psma Development Company, Llc | PSMA antibody-drug conjugates |
| CA2621502A1 (en) | 2005-09-07 | 2007-03-15 | Medimmune, Inc. | Toxin conjugated eph receptor antibodies |
| JP2010518115A (ja) * | 2007-02-09 | 2010-05-27 | ジェネンテック， インコーポレイテッド | 抗Ｒｏｂｏ４抗体およびそれらのための使用 |
| AU2008310908B2 (en) * | 2007-10-12 | 2014-01-09 | Seagen Inc. | Combination therapy with antibody-drug conjugates |
| CN101903403B (zh) * | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| UA115517C2 (uk) * | 2010-02-08 | 2017-11-27 | Ейдженсіс, Інк. | Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b |
-
2011
- 2011-02-08 UA UAA201210247A patent/UA115517C2/uk unknown
- 2011-02-08 BR BR112012019780-0A patent/BR112012019780A2/pt not_active Application Discontinuation
- 2011-02-08 WO PCT/US2011/024055 patent/WO2011097627A1/en not_active Ceased
- 2011-02-08 CA CA2789230A patent/CA2789230C/en active Active
- 2011-02-08 CN CN201610972361.1A patent/CN106975082A/zh active Pending
- 2011-02-08 KR KR1020127023540A patent/KR101510413B1/ko active Active
- 2011-02-08 ES ES11740529T patent/ES2668645T3/es active Active
- 2011-02-08 EA EA201201120A patent/EA201201120A1/ru unknown
- 2011-02-08 EP EP18162821.5A patent/EP3395361A1/en not_active Withdrawn
- 2011-02-08 AU AU2011213609A patent/AU2011213609B2/en active Active
- 2011-02-08 TW TW100104156A patent/TWI504410B/zh active
- 2011-02-08 US US13/022,905 patent/US8609092B2/en active Active
- 2011-02-08 CN CN201180008612XA patent/CN102844045A/zh active Pending
- 2011-02-08 MX MX2012008884A patent/MX2012008884A/es active IP Right Grant
- 2011-02-08 EP EP11740529.0A patent/EP2533804B1/en active Active
- 2011-02-08 PH PH1/2012/501545A patent/PH12012501545B1/en unknown
- 2011-02-08 JP JP2012552152A patent/JP6046494B2/ja active Active
-
2012
- 2012-07-31 IL IL221205A patent/IL221205A/en active IP Right Grant
-
2013
- 2013-12-13 US US14/106,444 patent/US9308278B2/en active Active
-
2016
- 2016-03-15 US US15/071,146 patent/US20160256563A1/en not_active Abandoned
- 2016-11-17 JP JP2016223674A patent/JP6529478B2/ja active Active
-
2017
- 2017-01-30 AU AU2017200600A patent/AU2017200600B2/en active Active
-
2018
- 2018-11-29 AU AU2018271337A patent/AU2018271337A1/en not_active Abandoned
- 2018-12-11 US US16/216,841 patent/US20190328898A1/en not_active Abandoned
-
2019
- 2019-05-14 JP JP2019091063A patent/JP2019131616A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518912A5 (OSRAM) | ||
| RU2423382C1 (ru) | Композиции и способы диагностики и лечения опухоли | |
| Metrangolo et al. | Antibody–drug conjugates: the dynamic evolution from conventional to next-generation constructs | |
| JP2012519711A5 (OSRAM) | ||
| RU2486198C2 (ru) | Антиген, ассоциированный с ревматоидным артритом | |
| JP2013543498A5 (OSRAM) | ||
| JP2017507936A5 (OSRAM) | ||
| JP2016509582A5 (OSRAM) | ||
| JP2014500862A5 (OSRAM) | ||
| RU2013142004A (ru) | Конъюгаты "антитело-лекарственное средство" | |
| JP2014533279A5 (OSRAM) | ||
| RU2015107889A (ru) | Композиция, содержащая два антитела, сконструированных так, чтобы они обладали пониженной и повышенной эффекторной функцией | |
| JP2012100677A5 (OSRAM) | ||
| JP2015525791A5 (OSRAM) | ||
| JP2013100314A5 (OSRAM) | ||
| JP2017110002A5 (OSRAM) | ||
| JP2012102122A5 (OSRAM) | ||
| RU2011140491A (ru) | Конъюгаты антитело-лекарственное средство, которые связывают белки 24р4с12 | |
| JP2017522861A5 (OSRAM) | ||
| JP2011103891A5 (OSRAM) | ||
| JP2012067116A5 (OSRAM) | ||
| JP2009521206A5 (OSRAM) | ||
| SG170730A1 (en) | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 | |
| JP2015534579A5 (OSRAM) | ||
| JP2009506790A5 (OSRAM) |